GÖKSU, S. Et Al. 2021. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.. Cancer chemotherapy and pharmacology , vol.88, no.5 , 805-812.

GÖKSU, S., TATLI, A. M., GEREDELI, C., ATCI, M., Besen, A. A., Mertsoylu, H., ... UYSAL, M.(2021). Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.. Cancer chemotherapy and pharmacology , vol.88, no.5, 805-812.

GÖKSU, SEMA Et Al. "Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.," Cancer chemotherapy and pharmacology , vol.88, no.5, 805-812, 2021

GÖKSU, SEMA S. Et Al. "Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.." Cancer chemotherapy and pharmacology , vol.88, no.5, pp.805-812, 2021

GÖKSU, S. Et Al. (2021) . "Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.." Cancer chemotherapy and pharmacology , vol.88, no.5, pp.805-812.

@article{article, author={SEMA SEZGİN GÖKSU Et Al. }, title={Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.}, journal={Cancer chemotherapy and pharmacology}, year=2021, pages={805-812} }